This site is intended for healthcare professionals

Mayzent is approved in Canada to treat secondary progressive multiple sclerosis.- Novartis

Read time: 1 mins
Published:14th Mar 2020
Novartis Pharmaceuticals Canada Inc. announces that Health Canada has approved Mayzent (siponimod) for the treatment of adults with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability. SPMS follows a relapsing-remitting (RRMS) course of multiple sclerosis (MS) and is characterized by progressive worsening with fewer, or no relapses, and nerve damage or loss. SPMS is defined as active when individuals experience relapses or there is evidence of new MRI activity..
Condition: Multiple Sclerosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.